Ines Schroeder1, Christina Scharf2, Michael Zoller2, Dietmar Wassilowsky2, Sandra Frank2, Stephanie-Susanne Stecher3, Joachim Stemmler4, Nikolaus Kneidinger5, Sven Peterß6, Bernhard Zwißler2, Michael Irlbeck2. 1. Klinik für Anästhesiologie, LMU Klinikum, Marchioninistr. 15, 81377, München, Deutschland. ines.schroeder@med.uni-muenchen.de. 2. Klinik für Anästhesiologie, LMU Klinikum, Marchioninistr. 15, 81377, München, Deutschland. 3. Medizinische Klinik und Poliklinik II, LMU Klinikum, Marchioninistr. 15, 81377, München, Deutschland. 4. Medizinische Klinik und Poliklinik III, LMU Klinikum, Marchioninistr. 15, 81377, München, Deutschland. 5. Medizinische Klinik und Poliklinik V, Deutsches Zentrum für Lungenforschung (DZL), LMU Klinikum, Marchioninistr. 15, 81377, München, Deutschland. 6. Herzchirurgische Klinik und Poliklinik, LMU Klinikum, Marchioninistr. 15, 81377, München, Deutschland.
Abstract
BACKGROUND: In a pandemic situation the overall mortality rate is of considerable interest; however, these data must always be seen in relation to the given healthcare system and the availability of local level of care. A recently published German data evaluation of more than 10,000 COVID-19 patients treated in 920 hospitals showed a high mortality rate of 22% in hospitalized patients and of more than 50% in patients requiring invasive ventilation. Because of the high infection rates in Bavaria, a large number of COVID-19 patients with considerable severity of disease were treated at the intensive care units of the LMU hospital. The LMU hospital is a university hospital and a specialized referral center for the treatment of patients with acute respiratory distress syndrome (ARDS). OBJECTIVE: Data of LMU intensive care unit (ICU) patients were systematically evaluated and compared with the recently published German data. METHODS: Data of all COVID-19 patients with invasive and noninvasive ventilation and with completed admission at the ICU of the LMU hospital until 31 July 2020 were collected. Data were processed using descriptive statistics. RESULTS: In total 70 critically ill patients were included in the data evaluation. The median SAPS II on admission to the ICU was 62 points. The median age was 66 years and 81% of the patients were male. More than 90% were diagnosed with ARDS and received invasive ventilation. Treatment with extracorporeal membrane oxygenation (ECMO) was necessary in 10% of the patients. The median duration of ventilation was 16 days, whereby 34.3% of patients required a tracheostomy. Of the patients 27.1% were transferred to the LMU hospital from external hospitals with reference to our ARDS/ECMO program. Patients from external hospitals had ARDS of higher severity than the total study population. In total, nine different substances were used for virus-specific treatment of COVID-19. The most frequently used substances were hydroxychloroquine and azithromycin. Immunomodulatory treatment, such as Cytosorb® (18.6%) and methylprednisolone (25.7%) were also frequently used. The overall in-hospital mortality rate of ICU patients requiring ventilation was 28.6%. The mortality rates of patients from external hospitals, patients with renal replacement therapy and patients with ECMO therapy were 47.4%, 56.7% and 85.7%, respectively. CONCLUSION: The mortality rate in the ventilated COVID-19 intensive care patients was considerably different from the general rate in Germany. The data showed that treatment in an ARDS referral center could result in a lower mortality rate. Low-dose administration of steroids may be another factor to improve patient outcome in a preselected patient population. In the authors' opinion, critically ill COVID-19 patients should be treated in an ARDS center provided that sufficient resources are available.
BACKGROUND: In a pandemic situation the overall mortality rate is of considerable interest; however, these data must always be seen in relation to the given healthcare system and the availability of local level of care. A recently published German data evaluation of more than 10,000 COVID-19 patients treated in 920 hospitals showed a high mortality rate of 22% in hospitalized patients and of more than 50% in patients requiring invasive ventilation. Because of the high infection rates in Bavaria, a large number of COVID-19 patients with considerable severity of disease were treated at the intensive care units of the LMU hospital. The LMU hospital is a university hospital and a specialized referral center for the treatment of patients with acute respiratory distress syndrome (ARDS). OBJECTIVE: Data of LMU intensive care unit (ICU) patients were systematically evaluated and compared with the recently published German data. METHODS: Data of all COVID-19 patients with invasive and noninvasive ventilation and with completed admission at the ICU of the LMU hospital until 31 July 2020 were collected. Data were processed using descriptive statistics. RESULTS: In total 70 critically ill patients were included in the data evaluation. The median SAPS II on admission to the ICU was 62 points. The median age was 66 years and 81% of the patients were male. More than 90% were diagnosed with ARDS and received invasive ventilation. Treatment with extracorporeal membrane oxygenation (ECMO) was necessary in 10% of the patients. The median duration of ventilation was 16 days, whereby 34.3% of patients required a tracheostomy. Of the patients 27.1% were transferred to the LMU hospital from external hospitals with reference to our ARDS/ECMO program. Patients from external hospitals had ARDS of higher severity than the total study population. In total, nine different substances were used for virus-specific treatment of COVID-19. The most frequently used substances were hydroxychloroquine and azithromycin. Immunomodulatory treatment, such as Cytosorb® (18.6%) and methylprednisolone (25.7%) were also frequently used. The overall in-hospital mortality rate of ICU patients requiring ventilation was 28.6%. The mortality rates of patients from external hospitals, patients with renal replacement therapy and patients with ECMO therapy were 47.4%, 56.7% and 85.7%, respectively. CONCLUSION: The mortality rate in the ventilated COVID-19 intensive care patients was considerably different from the general rate in Germany. The data showed that treatment in an ARDS referral center could result in a lower mortality rate. Low-dose administration of steroids may be another factor to improve patient outcome in a preselected patient population. In the authors' opinion, critically ill COVID-19 patients should be treated in an ARDS center provided that sufficient resources are available.
Authors: Timothy M Rawson; Luke S P Moore; Nina Zhu; Nishanthy Ranganathan; Keira Skolimowska; Mark Gilchrist; Giovanni Satta; Graham Cooke; Alison Holmes Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 9.079
Authors: Saskia Middeldorp; Michiel Coppens; Thijs F van Haaps; Merijn Foppen; Alexander P Vlaar; Marcella C A Müller; Catherine C S Bouman; Ludo F M Beenen; Ruud S Kootte; Jarom Heijmans; Loek P Smits; Peter I Bonta; Nick van Es Journal: J Thromb Haemost Date: 2020-07-27 Impact factor: 5.824
Authors: Leo Nicolai; Alexander Leunig; Kami Pekayvaz; Konstantin Stark; Sophia Brambs; Rainer Kaiser; Tobias Weinberger; Michael Weigand; Maximilian Muenchhoff; Johannes C Hellmuth; Stephan Ledderose; Heiko Schulz; Clemens Scherer; Martina Rudelius; Michael Zoller; Dominik Höchter; Oliver Keppler; Daniel Teupser; Bernhard Zwißler; Michael von Bergwelt-Baildon; Stefan Kääb; Steffen Massberg Journal: Circulation Date: 2020-07-28 Impact factor: 29.690
Authors: D J Hoechter; A Becker-Pennrich; J Langrehr; M Bruegel; B Zwissler; S Schaefer; M Spannagl; L C Hinske; M Zoller Journal: Thromb Res Date: 2020-08-21 Impact factor: 3.944
Authors: Jonathan E Millar; Reinhard Busse; John F Fraser; Christian Karagiannidis; Daniel F McAuley Journal: Lancet Respir Med Date: 2020-08-21 Impact factor: 30.700